129 related articles for article (PubMed ID: 3111089)
1. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Edwards CA; Piet MP; Chin S; Horowitz B
Vox Sang; 1987; 52(1-2):53-9. PubMed ID: 3111089
[TBL] [Abstract][Full Text] [Related]
2. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
Prince AM; Horowitz B; Brotman B
Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.
Horowitz B; Wiebe ME; Lippin A; Stryker MH
Transfusion; 1985; 25(6):516-22. PubMed ID: 3934801
[TBL] [Abstract][Full Text] [Related]
4. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.
Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B
Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772
[TBL] [Abstract][Full Text] [Related]
5. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
6. Purification of fibroblast growth factor-2 from human placenta using tri(n-butyl)phosphate and sodium cholate.
Wolff P; Tanaka AM; Chenker E; Cabrera-Crespo J; Raw I; Ho PL
Biochimie; 1996; 78(3):190-4. PubMed ID: 8831950
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids.
Horowitz B; Piët MP; Prince AM; Edwards CA; Lippin A; Walakovits LA
Vox Sang; 1988; 54(1):14-20. PubMed ID: 2831669
[TBL] [Abstract][Full Text] [Related]
8. Virus removal or inactivation in hemoglobin solutions by ultrafiltration or detergent/solvent treatment.
Bechtel MK; Bagdasarian A; Olson WP; Estep TN
Biomater Artif Cells Artif Organs; 1988; 16(1-3):123-8. PubMed ID: 2846096
[TBL] [Abstract][Full Text] [Related]
9. Quantitative determination of residual sodium-cholate in tri(N-butyl)phosphate/sodium-cholate treated factor VIII-preparations.
Dengler T; Kellner S; Fürst G
Vox Sang; 1989; 57(3):161-3. PubMed ID: 2515653
[TBL] [Abstract][Full Text] [Related]
10. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
11. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
Roberts PL; Dunkerley C
Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assays for evaluation of HTLV-III inactivation procedures: tri(N-butyl)phosphate:sodium cholate and beta-propiolactone.
Prince AM; Horowitz B; Dichtelmueller H; Stephan W; Gallo RC
Cancer Res; 1985 Sep; 45(9 Suppl):4592s-4594s. PubMed ID: 2410108
[TBL] [Abstract][Full Text] [Related]
13. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
14. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.
Horowitz MS; Rooks C; Horowitz B; Hilgartner MW
Lancet; 1988 Jul; 2(8604):186-9. PubMed ID: 2899662
[TBL] [Abstract][Full Text] [Related]
15. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
16. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
Michalski C; Bal F; Burnouf T; Goudemand M
Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
[TBL] [Abstract][Full Text] [Related]
17. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
[TBL] [Abstract][Full Text] [Related]
18. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants.
Chin S; Williams B; Gottlieb P; Margolis-Nunno H; Ben-Hur E; Hamman J; Jin R; Dubovi E; Horowitz B
Blood; 1995 Dec; 86(11):4331-6. PubMed ID: 7492794
[TBL] [Abstract][Full Text] [Related]
19. Investigations into the application of tri(n-butyl)phosphate/detergent mixtures to blood derivatives.
Horowitz B
Curr Stud Hematol Blood Transfus; 1989; (56):83-96. PubMed ID: 2642786
[No Abstract] [Full Text] [Related]
20. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
